

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

claims 1, 2, 5-7, 9, 11 and 27 have been amended; and  
claims 23 and 24 have been canceled.

**Listing of Claims:**

Claim 1 (currently amended): A site-specific drug delivery medical device having a coating consisting essentially of a ~~site-specific delivery device for the controlled release of~~ at least one peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) agonist and at least one biocompatible polymer.

Claim 2 (currently amended): The site-specific drug delivery medical device according to claim 1 wherein said PPAR $\gamma$  agonist is rosiglitazone.

Claim 3 (canceled)

Claim 4 (canceled)

Claim 5 (currently amended): The site-specific drug delivery medical device according to any of claims 1 or 2 wherein said medical device is a stent.

Claim 6 (currently amended): The site-specific drug delivery medical device according to claim 5 wherein said stent is a vascular stent or biliary stent.

Claim 7 (currently amended): The site-specific drug delivery medical device according to claim 6 wherein said vascular stent is provided with a coating consisting essentially of rosiglitazone and at least one biocompatible polymer.

Claim 8 (canceled)

Claim 9 (currently amended): The site-specific drug delivery medical device according to claim 1 wherein said biocompatible polymer is selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid,

polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

Claim 10 (canceled)

Claim 11 (currently amended): A vascular stent ~~medical device~~ consisting essentially of ~~a vascular stent and rosiglitazone~~; and

a polymer selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

Claims 12-26 (canceled)

Claim 27 (currently amended): The site-specific drug delivery medical device according to claim 7 wherein said biocompatible polymer is selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.